Hydreight Technologies Inc. (TSXV: NURS) reported record Q2 2026 revenue of C$28.0 million, up 421% from C$5.4 million a year earlier, as pharmacy sales and its VSDHOne direct-to-consumer healthcare infrastructure expanded rapidly across the United States. Gross profit increased 182% to C$5.4 million, net income rose to C$2.53 million from approximately C$50,000 and adjusted EBITDA reached C$3.22 million compared with C$182,000 in Q2 2025. For the first six months, revenue climbed 434% to C$53.0 million and net income reached C$5.12 million.
The results were released at 10:25 p.m. Eastern Time on August 31, well after the TSX Venture Exchange had closed. Hydreight had finished the August 31 session at C$4.14, up 4.28% from the previous C$3.97 close, but that move preceded publication of the Q2 numbers and cannot be attributed to the earnings release. The first valid post-results session is September 1, which remained in progress when this article was prepared. NURS entered that session with an approximately C$213 million market capitalisation and a 52-week range of C$2.38 to C$5.59.
How did Hydreight turn C$5.4 million of quarterly revenue into C$28 million in one year?
The largest contributor was pharmacy product sales, which jumped to approximately C$26.2 million from C$4.5 million in Q2 2025. Hydreight’s virtual-healthcare and direct-to-consumer segment generated about C$22.8 million of quarterly revenue compared with only C$0.7 million a year earlier, while six-month revenue from that segment reached C$42.7 million versus roughly C$1 million in the corresponding 2025 period. Growth was driven by VSDHOne platform utilisation, additional business partners, renewals and expansion of available healthcare products and treatments.
VSDHOne is designed to provide businesses with the compliance, telemedicine, physician-network and pharmacy infrastructure required to launch direct-to-consumer healthcare offerings across the United States. Hydreight said its broader network now includes more than 3,000 nurses and over 300 independent doctors, alongside pharmacy relationships spanning all 50 states. The platform supports categories including GLP-1 therapies, peptides, testosterone replacement therapy, hair-loss treatments, skincare and sexual-health services.
The scale-up means Hydreight is increasingly functioning as healthcare infrastructure rather than simply as a mobile-medical-services company. Businesses using VSDHOne can access technology and clinical networks without recreating each component independently, creating an opportunity for Hydreight to participate in transaction volumes across multiple consumer-health brands.
Why did Hydreight’s gross margin fall despite gross profit increasing 182%?
The revenue mix shifted heavily toward pharmacy products. Q2 gross profit of C$5.44 million on C$28.03 million of IFRS revenue implies a gross margin of approximately 19.4%, compared with roughly 35.9% on C$1.93 million of gross profit and C$5.38 million of revenue a year earlier. Hydreight said the percentage decline reflected pharmacy sales becoming a much larger proportion of revenue and initial pricing concessions connected with several new compounding-pharmacy relationships.
Management generally targets approximately 20% margins on pharmacy sales before discounts and incentives, although actual economics differ by product, manufacturer and promotional activity. That means continued rapid pharmacy growth can increase absolute gross profit while simultaneously lowering consolidated gross-margin percentages compared with a business mix carrying more software, platform or service revenue.
Net income nevertheless reached approximately 9% of quarterly revenue, while adjusted EBITDA represented roughly 11.5%. Hydreight therefore remained profitable despite the lower gross-margin percentage, although Q2 net income and adjusted EBITDA were broadly similar to Q1 even as revenue increased another 12.5%. That sequential relationship suggests investors should increasingly watch incremental profitability rather than revenue growth alone.
Can Hydreight realistically reach C$150 million of FY26 revenue after generating C$53 million in H1?
Hydreight reaffirmed its approximately C$150 million FY26 revenue guidance. With C$52.97 million recognised during the first six months, achieving that target requires roughly C$97 million of revenue during the second half. That is approximately 83% more than H1 revenue and requires an average of about C$48.5 million per quarter during Q3 and Q4.
The quarterly comparison makes the hurdle even clearer. Average required H2 revenue would be approximately 73% above the record C$28.0 million produced in Q2. Hydreight therefore needs more than simply maintaining its current growth rate sequentially; it needs substantial additional partner activity, pharmacy capacity and transaction volumes during the final six months.
Management says guidance depends on assumptions including partner activity, transaction volumes, service mix and pharmacy capacity utilisation. The target therefore remains explicitly forward-looking rather than contracted revenue. VSDHOne expansion and new treatment lines provide a route toward that scale, but the gap between H1 performance and the full-year target is now one of the most important measurable questions in the investment case.
Why is Hydreight using cash even though the business is profitable?
Hydreight finished June with approximately C$20 million of cash and C$35 million of working capital, up from C$15.6 million of cash and C$15.7 million of working capital at December 31. Yet the company used approximately C$8.7 million of cash in operating activities during the first half despite reporting C$5.1 million of net income.
The difference largely reflects working-capital investment required to support rapidly expanding pharmacy activity. Hydreight and its subsidiaries provide funding and other support for pharmacy partners establishing new product and treatment lines, which can require capital for inventory and operating infrastructure before the associated revenue is fully collected. Pharmacy product sales reached C$26.2 million in Q2 alone, making working-capital management increasingly important as the business scales.
Hydreight also invested approximately C$0.8 million into VSDHOne 2.0 during the first six months, with the next-generation platform intended to improve scalability, security and technology infrastructure. The balance sheet gives the company capacity to continue that investment, but sustained positive earnings will eventually need to translate into operating cash generation if revenue grows toward management’s C$150 million target.
What does Hydreight’s C$213 million valuation imply after its record quarter?
At the C$4.14 August 31 close, Hydreight was valued at approximately C$213 million, or about four times trailing revenue of roughly C$56 million. That relationship could compress rapidly if the company approaches its C$150 million guidance while retaining profitability, but it could expand just as quickly if the revenue target proves too ambitious or gross-margin compression continues.
The stock was almost unchanged over the month to August 31 despite considerable volatility, closing at C$4.14 compared with approximately C$3.99 on July 31. Shares had traded as high as C$4.30 during August and remain below the C$5.59 52-week high.
The Q2 result establishes that Hydreight’s rapid growth is now producing real accounting profits rather than merely gross transaction volume. The tougher question moves to scale quality. With pharmacy revenue increasingly dominant, investors need to see whether gross profit, EBITDA and cash generation can keep pace as Hydreight attempts to produce almost C$100 million of additional revenue during the remaining half of 2026.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
